Narayana Hrudayalaya Ltd.
NSE: NHNarayana Hrudayalaya Ltd.: A 30-second snapshot
Narayana Hrudayalaya trades at ₹2,072.8, within 0.9% of its 52-week high and above both its 50-DMA (₹1,947.8) and 200-DMA (₹1,844.0) after a 17.59% three-month advance. Return on equity is 19.85% (above 15% in 4 of the tracked years) against a debt-to-equity of 129.0% on a rising trend, with a mean analyst rating of 1.71 across 14 analysts (1-5 scale, lower = more constructive). Recent news centers on a ₹1,500 crore capital raise, a ₹4.50/share dividend declaration, and FY2025-26 consolidated revenue up 44% YoY to ₹78,960.35 million.
P/E
52.0
Forward P/E
29.5
ROE
+19.9%
Debt / Equity
129.03
Profit Margin
+10.2%
Div. Yield
+0.2%
5Y ROE > 15%
4/5
5Y FCF > 0
3/5
Quality
66/100
News
8 headlines · 7 positive · 0 negative
Narayana Hrudayalaya Submits FY 2025-26 Annual Report; Consolidated Revenue Surges 44% to ₹78,960.35 Million
scanx.trade
Narayana Hrudayalaya: ₹1500 करोड़ जुटाएगी कंपनी, ₹4.50 प्रति शेयर डिविडेंड का ऐलान - Whalesbook
Whalesbook
Narayana Hrudayalaya: షేర్ హోల్డర్లకు శుభవార్త.. ₹1,500 కోట్ల ఫండ్ రైజింగ్, ₹4.50 డివిడెండ్! - Whalesbook
Whalesbook
Narayana Hrudayalaya Share Price: गुंतवणूकदारांसाठी आनंदाची बातमी! कंपनी देणार ₹4.50 डिव्हिडंड, वाढवणार ₹1500 कोटींचे कर्ज - Whalesbook
Whalesbook
Narayana Hrudayalaya: ₹1,500 કરોડનું દેવું અને ₹4.50 ડિવિડન્ડ, AGMમાં થશે વિચારણા - Whalesbook
Whalesbook
Recent context
- ·FY2025-26 annual report showed consolidated revenue up 44% YoY to ₹78,960.35 million.
- ·Company announced a planned ₹1,500 crore fundraise alongside a ₹4.50/share dividend, per July 23 coverage.
- ·All 8 tracked news items carry positive or neutral sentiment (7 positive, 1 neutral, 0 negative).
Strengths
- +ROE of 19.85%, sustained above 15% in 4 of the tracked years (consistency score 66).
- +ROE ranks 2nd of 6 sector peers and quality score of 44 ranks 2nd of 6.
- +Price trades above both the 50-DMA and 200-DMA, within 0.9% of its 52-week high, up 17.59% over the last 3 months.
- +Mean analyst rating of 1.71 across 14 analysts (1-5 scale, lower = more constructive); FY2025-26 consolidated revenue grew 44% YoY to ₹78,960.35 million per the annual report.
Weaknesses
- −Debt-to-equity of 129.0% on a rising trend, with free cash flow positive in only 3 of the tracked years.
- −5-year revenue growth of 75.8% outpaces 5-year earnings growth of 13.5% by a wide margin; net profit margin sits at 10.2%.
- −PE of 52.03 (forward PE 29.51) ranks 4th of 6 peers, more expensive than Sun Pharma (41.59), Cipla (35.31) and Dr. Reddy's (28.74).
- −News sample of 8 articles is concentrated in two underlying stories republished across multiple language editions, limiting independent signal diversity.
Open questions
- ?Does the planned ₹1,500 crore raise consist of debt, equity, or a mix, and how would each route affect the current 129% debt-to-equity on its rising trend?
- ?What structural or one-off factors explain 5-year earnings growth of 13.5% trailing 5-year revenue growth of 75.8%?
- ?Is the price level near the 52-week high supported by a distinct fundamental catalyst, or largely a continuation of the recent 3-month momentum?
- ?How does NH's quality score of 44 and PE of 52.03 compare with sector leader Sun Pharma's quality score of 56 on a like-for-like basis?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| NH | Narayana Hrudayalaya Ltd.You're viewing | 52.0 | +19.9% | 44 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 75.1 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.3 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.7 | +8.8% | 4 |
Technical state
Current price
₹2,072.80
SMA 50
₹1,947.80
SMA 200
₹1,843.99
RSI (14)
63.4 (neutral)
From 52w high
-0.9%
1Y return
+5.1%
3M return
+17.6%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- mediumDebt-to-equity stands at 129.0% on a rising debt trend, while free cash flow was positive in only 3 of the tracked years, narrowing the buffer available to service growing obligations.
- medium5-year revenue growth of 75.8% far outpaces 5-year earnings growth of 13.5%; current net profit margin is 10.2%, indicating the top-line expansion has not converted proportionally to the bottom line.
- lowPrice is within 0.9% of its 52-week high after a 17.59% 3-month advance, with RSI at 63.4 in the upper end of the neutral range.
- lowNews sample of 8 articles is concentrated in two underlying stories (the capital-raise/dividend announcement and the annual report), republished across multiple language editions, which limits the diversity of independent signal.
Cross-section contradictions
- News flow highlights a planned ₹1,500 crore capital raise announced alongside a ₹4.50/share dividend, while fundamental data shows a rising debt trend and free cash flow positive in only 3 of the tracked years — raising capital and distributing cash are occurring against an already leveraged, rising-debt balance sheet.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 30 Jul 2026 · rotates through NIFTY 500 every ~5 days